2,758 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by Semanteon Capital Management LP

Semanteon Capital Management LP purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 2,758 shares of the biopharmaceutical company's stock, valued at approximately $759,000.

A number of other large investors have also recently bought and sold shares of ALNY. Capital Research Global Investors grew its position in Alnylam Pharmaceuticals by 7.3% in the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company's stock valued at $470,018,000 after acquiring an additional 214,908 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Alnylam Pharmaceuticals by 5.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company's stock worth $550,837,000 after purchasing an additional 201,784 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 92.5% during the second quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company's stock worth $65,862,000 after purchasing an additional 130,482 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth $18,886,000. Finally, Deerfield Management Company L.P. Series C bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $29,111,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Trading Up 0.7 %

Shares of NASDAQ ALNY traded up $2.05 during mid-day trading on Monday, reaching $286.91. 521,370 shares of the company's stock were exchanged, compared to its average volume of 868,200. The firm has a market capitalization of $36.29 billion, a price-to-earnings ratio of -107.06 and a beta of 0.39. The business has a fifty day simple moving average of $274.68 and a 200 day simple moving average of $223.34. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. The company's revenue for the quarter was up 107.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.21) EPS. Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the transaction, the director now directly owns 136 shares in the company, valued at approximately $35,632. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $20,563,480. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the transaction, the director now owns 136 shares of the company's stock, valued at $35,632. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,398 shares of company stock worth $13,595,460. 1.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ALNY shares. Needham & Company LLC restated a "buy" rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday, October 10th. Bank of America increased their target price on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a "buy" rating in a report on Monday, October 14th. Raymond James upped their price target on Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the company an "outperform" rating in a research note on Friday, August 2nd. Morgan Stanley upped their price target on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the company an "equal weight" rating in a research note on Friday, July 12th. Finally, Wells Fargo & Company upped their price target on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an "equal weight" rating in a research note on Friday, August 2nd. Six equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $290.86.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.